Mechanism and basics

how does retatrutide work

Published May 2, 2026Updated May 3, 2026Medical safety, official-source, and research-reference review

Retatrutide is often nicknamed GLP-3, but Lilly says triple agonist is the more accurate term.

Direct answer

Retatrutide is designed to activate three hormone receptor pathways: GIP, GLP-1, and glucagon. Lilly describes it as an investigational once-weekly triple hormone receptor agonist.

Research context

These references frame the evidence base behind this topic. They are not medical advice, approval, or instructions for using retatrutide outside a clinical trial.

Short source quoteagonist of the GIP, GLP-1, and glucagon receptors

Jastreboff et al., NEJM 2023 retatrutide phase 2 obesity trial

This peer-reviewed phase 2 paper is the anchor for retatrutide mechanism language. It does not make retatrutide approved or publicly available.

Short source quoterandomised, double-blind, placebo and active-controlled

Rosenstock et al., Lancet 2023 retatrutide phase 2 type 2 diabetes trial

The type 2 diabetes phase 2 paper helps separate controlled clinical research from online self-use claims.

Short source quoterandomized, double-blind, placebo-controlled trial

Sanyal et al., Nature Medicine 2024 retatrutide MASLD phase 2a trial

The MASLD substudy adds peer-reviewed evidence for metabolic research context, but it is still not public-use approval.

Short source quotecombining the activity of GLP-1, GIP, and glucagon

Bossart et al., Cell Metabolism 2022 GLP-1/GIP/glucagon triagonist study

This triagonist paper supports the broader triple-agonist mechanism discussion, not claims about any unapproved product sold online.

Short source quotebiological actions, and therapeutic relevance

Baggio and Drucker, Gastroenterology 2007 biology of incretins review

This review supports mechanism explanations around GLP-1 and GIP biology without turning mechanism into treatment advice.

What to know before acting on this search

GLP-1 and GIP pathways are involved in appetite, glucose, and metabolic signaling.
Glucagon receptor activity is part of why retatrutide is described differently from semaglutide and tirzepatide.
Mechanism does not equal approval; regulators still review safety, efficacy, manufacturing, and labeling.

Safety and compliance notes

The informal label GLP-3 can mislead users into thinking retatrutide is an approved next-generation GLP product.
Trial results are population averages and do not predict a specific person's result.
Side effects and contraindications need clinician review if a drug is ever approved for a patient.

Safer next step

Read the GLP-3 guide and clinical-trials page for mechanism and evidence context.

Medical disclaimer

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. Retatrutide is investigational and is not FDA approved. FDA-approved options such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.